Keymed Biosciences Future Growth
Future criteria checks 2/6
Keymed Biosciences's earnings are forecast to decline at 9.1% per annum while its annual revenue is expected to grow at 36.4% per year. EPS is expected to decline by 7.5% per annum. Return on equity is forecast to be -53% in 3 years.
Key information
-9.1%
Earnings growth rate
-7.5%
EPS growth rate
Biotechs earnings growth | 35.4% |
Revenue growth rate | 36.4% |
Future return on equity | -53.0% |
Analyst coverage | Good |
Last updated | 09 May 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,228 | -502 | -701 | -394 | 9 |
12/31/2025 | 569 | -754 | -832 | -600 | 10 |
12/31/2024 | 116 | -830 | -959 | -670 | 8 |
12/31/2023 | 354 | -359 | -635 | -304 | N/A |
9/30/2023 | 341 | -313 | -587 | -250 | N/A |
6/30/2023 | 327 | -267 | -539 | -197 | N/A |
3/31/2023 | 214 | -287 | -610 | -299 | N/A |
12/31/2022 | 100 | -308 | -681 | -402 | N/A |
9/30/2022 | 155 | -281 | -661 | -349 | N/A |
6/30/2022 | 210 | -253 | -640 | -295 | N/A |
3/31/2022 | 160 | -2,070 | -514 | -255 | N/A |
12/31/2021 | 110 | -3,887 | -387 | -215 | N/A |
9/30/2021 | 55 | -4,149 | -269 | -169 | N/A |
6/30/2021 | N/A | -4,412 | -150 | -124 | N/A |
3/31/2021 | N/A | -2,615 | -145 | -122 | N/A |
12/31/2020 | N/A | -819 | -139 | -119 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2162 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2162 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2162 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2162's revenue (36.4% per year) is forecast to grow faster than the Hong Kong market (8.1% per year).
High Growth Revenue: 2162's revenue (36.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2162 is forecast to be unprofitable in 3 years.